Exploring Naloxone Uptake and Use – A Public Meeting

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), in collaboration with the National Institutes of Drug Abuse, the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration, and the Health Resources and Services Administration, is announcing a scientific workshop to initiate a public discussion about issues surrounding the uptake of naloxone in certain medical settings – such as on ambulances and in association with prescriptions for opioids – as well as outside of conventional medical settings to reduce the incidence of opioid overdose fatalities. Academia, government, industry experts, and patient advocates will discuss which populations are at risk for opioid overdose and how public health groups can work together to use naloxone to reduce the risk of overdose. We will also explore legal, regulatory, logistical and clinical aspects related to making naloxone more widely available.

Date(s) and Time(s)

July 1, 2015 from 8:00 a.m. to 5:00 p.m.
July 2, 2015 from 8:00 a.m. to 3:00 p.m.


FDA White Oak Campus
10903 New Hampshire Ave.
Building 31 Conference Center
the Great Room (Rm. 1503)
Silver Spring, MD 20993-0002


Registration should be submitted to NaloxoneWorkshop@fda.hhs.gov by June 22, 2015



Page Last Updated: 10/27/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English